Switching from a Non-Protease Inhibitor-Based Regimen to the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice [Corrigendum]

Switching from a Non-Protease Inhibitor-Based Regimen to the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice [Corrigendum]

Ranzenigo M, Gianotti N, Galli L, et al. Drug Des Devel Ther. 2022;16:1975–1982. Page 1975, Abstract, Results, line five, the text “the ongoing regimen was based on NNRTIs in 37 (35%) and on InSTIs in 69 (65%)” should read “the ongoing regimen was based on NNR...

Full description

Bibliographic Details
Main Authors: Ranzenigo M, Gianotti N, Galli L, Poli A, Mastrangelo A, Bruzzesi E, Chiurlo M, Nozza S, Bossolasco S, Spagnuolo V, Mancusi D, Termini R, Carini E, Lazzarin A, Castagna A
Format: Article
Language:English
Published: Dove Medical Press 2022-10-01
Series:Drug Design, Development and Therapy
Subjects:
treatment switching
anti-retroviral agents
hiv protease inhibitors
adverse drug events
sustained virologic response
Online Access:https://www.dovepress.com/corrigendum-switching-from-a-non-protease-inhibitor-based-regimen-to-t-peer-reviewed-fulltext-article-DDDT

Internet

https://www.dovepress.com/corrigendum-switching-from-a-non-protease-inhibitor-based-regimen-to-t-peer-reviewed-fulltext-article-DDDT

Similar Items